Inovio Pharmaceuticals, Inc. {NASDAQ: INO}, announced it ranked No. 107 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.
Inovio Wins Deloitte’s “Fast 500” Growth Award
Developer of DNA-based Immunotherapies Recognized For its Ability to Attract Grants and Partnerships
PLYMOUTH MEETING, Pa. – November 16, 2016 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO}, today announced it ranked No. 107 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.
Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2012 to 2015. During this period Inovio’s revenue growth reached 885.1%, based on revenue received from grants, partnerships and licensing deals.
Dr. J. Joseph Kim, Inovio’s President and CEO, said, “We appreciate Deloitte’s recognition of Inovio’s growth based on our advancement of DNA immunotherapies and vaccines for cancers and infectious diseases. Our growth is fueled by the innovative spirit of our scientists, engineers and business people. At our company’s core; however, the Inovio team is motivated by our most important value: “Patients are waiting.”
“This year’s Fast 500 winners showcase that when organizations are open to diverse perspectives and insights, they are able to create an environment for their employees and investors to see the possibilities and ingenious solutions that might lie ahead,” added Jim Atwell, Deloitte’s national managing partner of the emerging growth practice. “Entrepreneurial environments foster change and innovation within businesses, and we look forward to watching these companies continue to drive change across all sectors.”
About Deloitte’s 2016 Technology Fast 500™
Deloitte’s Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2012 to 2015. Overall, 2016 Technology Fast 500™ companies achieved revenue growth ranging from 121 percent to 66,661 percent from 2012 to 2015, with median growth of 290 percent.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $50,000 USD, and current-year operating revenues of at least $5 million USD. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.
For more information, please visit www.inovio.com
CONTACT:
Bernie Hertel
Inovio Pharmaceuticals
+1 858-410-3101